within Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G03F_ProgestogensAndEstrogensInCombination.G03FB01_NorgestrelAndEstrogen;

model NorgestrelAndEstrogen
  extends Pharmacolibrary.Drugs.ATC.G.G03FB01
  // parameters inherited from base class, duplicate, uncomment and change if necesarry
  /*
  
    weight         = 70,
    F              = 0.97,
    Cl             = 9.722222222222223e-06,
    adminDuration  = 600,
    adminMass      = 0.3 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018333333333333333,
    Tlag           = 600  
  */
  ;

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>NorgestrelAndEstrogen</td></tr><tr><td>ATC code:</td><td>G03FB01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.3</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>35</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Norgestrel and estrogen (commonly as ethinylestradiol) is a combination hormonal contraceptive used for prevention of pregnancy. This combination was widely used in oral contraceptive pills. Norgestrel is a synthetic progestogen and ethinylestradiol is a synthetic estrogen. The combination is approved for use as an oral contraceptive in many countries.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult women using standard oral contraceptive doses. No direct published sources for 'norgestrel and estrogen' combined PK model were found; parameters are estimated based on published PK studies of individual components.</p><h4>References</h4><ol><li><p>Kuhnz, W (1990). Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women. <i>American journal of obstetrics and gynecology</i> 163(6 Pt 2) 2120–2127. DOI:<a href=\"https://doi.org/10.1016/0002-9378(90)90551-h\">10.1016/0002-9378(90)90551-h</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2124087/\">https://pubmed.ncbi.nlm.nih.gov/2124087</a></p></li><li><p>Olsson, B, &amp; Landgren, BM (2001). The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. <i>Clinical therapeutics</i> 23(11) 1876–1888. DOI:<a href=\"https://doi.org/10.1016/s0149-2918(00)89083-9\">10.1016/s0149-2918(00)89083-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11768839/\">https://pubmed.ncbi.nlm.nih.gov/11768839</a></p></li><li><p>Anderson, MS, et al., &amp; Iwamoto, M (2011). Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. <i>British journal of clinical pharmacology</i> 71(4) 616–620. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2010.03885.x\">10.1111/j.1365-2125.2010.03885.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21395656/\">https://pubmed.ncbi.nlm.nih.gov/21395656</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end NorgestrelAndEstrogen;
